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ABSTRACT
Pancreatic cancer stem cells (CSCs) play a crucial role in tumorigenesis and 
chemoresistance of pancreatic ductal adenocarcinoma. Pancreatic adenocarcinoma 
up-regulated factor (PAUF), a novel secretory protein, has been shown to contribute 
to cancer progression and metastasis. Because the clinical relationship between PAUF 
and pancreatic CSCs is largely unknown, we investigated the associations between 
the functional role of PAUF and pancreatic CSCs. Pancreatic cancer sphere cultured 
from the CFPAC-1 cells showed elevated expression of PAUF and pluripotent stemness 
genes (Oct4, Nanog, Stat3, and Sox2), and the mRNA of PAUF were increased in 
CD44+CD24+ESA+ pancreatic CSCs. PAUF knockdown (shPAUF) CFPAC-1 diminished the 
number of spheres and decreased stemness genes and CSC surface markers (CD133, 
c-MET and ALDH1). In addition, siPAUF CFPAC-1 decreased the mRNA expression 
of multidrug resistant protein 5 (MRP5) and ribonucleotide reductase M2 (RRM2) 
and were more vulnerable to gemcitabine and 5-FU than negative control (p<0.05). 
In conclusion, PAUF was increased in pancreatic CSCs and the suppression of PAUF 
enhances chemotherapeutic response to gemcitabine and 5FU by decreasing MRP5 
and RRM2 in pancreatic cancer cells.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of 
the most aggressive malignancies and is the fourth leading 
cause of cancer-related death in the western world [1, 2]. 
The difficulty in early detection of PDAC and its resistance 
to conventional treatment options contribute to its dismal 
prognosis, as indicated by an overall 5-year survival rate 
of less than 10% [1, 2]. Many researchers have attempted 
to elucidate the pathogenesis and carcinogenesis of PDAC. 
However, the molecular basis for the aggressive nature 
of PDAC is incompletely understood, and the overall 
survival of patients has not improved significantly despite 
advances in treatment modalities and introduction of novel 
targeted therapies.
The clinical outcomes of PDAC may be poor 
because conventional therapies are directed at tumor cells 
that have limited tumorigenic potential instead of targeting 
the pancreatic cancer stem cells (CSCs) that have been 
identified in human PDAC [3]. Pancreatic CSCs are 
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identified by a variety of biomarkers, and transplantation 
assays using immune-deficient mice show that pancreatic 
CSCs self-renew and propagate the parental tumor. Li et al. 
has identified populations of CSCs in PDAC that express 
the cell surface markers CD44+CD24+ESA+or c-Met [3, 4]. 
Apart from these markers, CD133+ and ALDH1 are 
regarded as other markers of CSCs in PDAC [5–7]. These 
CSCs are also characterized by their chemoresistance, 
as CD133+ pancreatic cancer cells have greater drug 
resistance to gemcitabine [6], and c-MET inhibitors have 
been shown to enhance antitumor effects in combination 
with gemcitabine [3].
Genome-wide analyses have uncovered pancreatic 
adenocarcinoma up-regulated factor (PAUF), a novel 
secretory protein associated with pancreatic cancer [8]. 
Although the mechanism through which PAUF contributes 
to cancer progression is not clearly established, previous 
reports suggest it plays critical roles in PDAC progression 
and metastasis processes, including cell proliferation and 
modulation of adhesion, migration, and invasion [9–15].
No studies have investigated the association between 
PAUF and CSCs and how it may contribute to drug 
sensitivity and resistance. Therefore, the purpose of the 
present study was to investigate the relationship between 
PAUF function and pancreatic CSCs. Our experiments 
provided evidence of PAUF expression in pancreatic CSCs 
and suggested that PAUF may contributes to multi-drug 
resistance in the pancreatic CSCs.
RESULTS
Pancreatic cancer spheres cultured from human 
pancreatic cancer cell lines
We used sphere culture to identify CSCs. This 
in vitro method involved culturing candidate pancreatic 
CSCs with serum-free media containing only EGF and 
bFGF under nonadherent conditions, and the resulting 
spheres indicated self-renewal consistent with a CSC 
phenotype. In this study, PDAC spheres cultured from 
the CFPAC-1 cells showed upregulated expression of the 
pluripotent stemness genes Oct4, Nanog, Stat3, and Sox2 
relative to adherent CFPAC-1 cells (Figure 1A).
PAUF overexpression in pancreatic CSCs
We previously reported PAUF as a novel secretory 
protein associated with pancreatic cancer [8]. To show 
the relationship between the PAUF and pancreatic CSCs, 
secretory PAUF expression were detected in spheres 
and adherent CFPAC-1 cells by western blot analysis. 
As Figure 1B, PAUF expressions were upregulated in 
spheres than adherent CFPAC-1 cells. Furthermore, in 
other pancreatic cancer cells such as CAPAN-1 and HPAC 
cells, PAUF expression were upregulated in spheres than 
adherent cells (Figure 1B).
One of the other enrichment methods of CSCs is 
fluorescence-activated cell sorting (FACS) through cell 
surface marker. Based on previous reports that identified 
the cell surface markers CD44+CD24+ESA+ in a CSC 
population of human PDAC, we sorted the CFPAC-1 
cell line into CD44+CD24+ESA+ and CD44-CD24-ESA- 
cells using FACS (Figure 2A), and validated that the 
previous reported stemness gene expression level using 
RT-PCR (Figure 2B). Oct4, Nanog, Stat3, Sox2, CD133, 
c-Met, beta-catenin et al. genes expression levels were 
upregulated in CD44+CD24+ESA+ than in CD44-CD24-
ESA- CFPAC-1 cells. As well as, PAUF mRNA content 
was higher in CD44+CD24+ESA+ than in CD44-CD24-
ESA- CFPAC-1 cells (Figure 2B, 2C). Furthermore, in the 
other pancreatic cancer cell line of HPAC, the expressions 
of stemness related genes and PAUF were upregulated in 
CD44+CD24+ESA+ than in CD44-CD24-ESA- HPAC cells 
(Figure 2D, 2E).
PAUF knockdown effects on pancreatic cancer 
stem cells in pancreatic cancer cell lines
To further access the specific role of PAUF in 
pancreatic CSCs function, we stably knocked down PAUF 
expression using shRNA targeting regions of PAUF.
(Figure 3A) The shPAUF CFPAC-1 cells showed reduced 
cell proliferation, migration ability and in vivo xenograft 
tumor formation. Migration ability also decreased 
0.67-fold in shPAUF CFPAC-1 cells compared with 
NC CFPAC-1 cells (mean ± SD); 187.71 ± 41.33 cells/
microscopic field in shPAUF vs. 278.67 ± 28.66 cells/
microscopic field in NC (Figure 3B). To investigate 
the effect of PAUF knockdown on the xenograft tumor 
formation in vivo, both shPAUF and NC CFPAC-1 
cells were injected subcutaneously into nude mice. 
After 48 days, shPAUF CFPAC-1 cells formed 0.44-
fold smaller tumor compared with NC CFPAC-1 
cells (mean ± SD); the average tumor size was 114.5 
± 30.12 mm3 in shPAUF-xenografts vs. 258.0 ± 
103.0 mm3 in NC-xenograft mice (Figure 3C). The effect 
of PAUF knockdown on CSCs-related characteristics 
was determined using sphere formation and soft agar 
assay. The number of sphere formation was markedly 
diminished in shPAUF CFPAC-1 cells compared with 
NC CFPAC-1 cells. (Figure 3D). Furthermore, the soft 
agar assay showed that the number of colonies was also 
0.54-fold lower in the shPAUF CFPAC-1 cells (mean ± 
SD); 106.25 ± 0.24 colonies in shPAUF vs. 195.25 ± 0.10 
colonies in NC (Figure 3E).
The mRNA and protein expression of pluripotent 
stemness genes in shPAUF CFPAC-1 was measured using 
RT-PCR and western blot, respectively. The expression 
of stemness-related genes (including Oct4, Nanog, and 
Sox2), and CSC surface markers (such as CD44, CD133, 
and c-Met) were lower in the shPAUF CFPAC-1 than in 
the control CFPAC-1 cells (Figure 3F). Protein expression 
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Figure 1: PAUF overexpression in pancreatic cancer spheres. (A) RT-PCR showed that the overexpression of Oct4, Nanog, Stat3, 
and Sox2 genes in sphere formed from CFPAC-1 cells compare with adherent cells. (B) Up-regulation of secretory PAUF was determined 
by western blot in CFPAC-1, CAPAN-1 and HPAC spheres (Sp) than adherent (Ad) cells.
Figure 2: PAUF overexpression in CD24+/CD44+/ESA+ pancreatic CSCs. (A) CFPAC-1 cells were sorted using surface 
marker antibodies. CD24+/CD44+/ESA+ cells were 46% and CD24-/CD44-/ESA- cells were 52%. (B) RT-PCR demonstrated that the 
mRNA expression of stemness-related genes and PAUF was higher in CD24+/CD44+/ESA+ pancreatic CSCs sorted from CFPAC-1 
cells than in CD24-/CD44-/ESA- CFPAC-1 cells. (C) Bar graph demonstrated that quantitative analysis of RT-PCR data. (D) HPAC-1 
cells were sorted using surface marker antibodies. CD24+/CD44+/ESA+ cells were 19.1% and CD24-/CD44-/ESA- cells were 19.2%. 
(E) RT-PCR demonstrated that the mRNA expression of stemness-related genes and PAUF was higher in CD24+/CD44+/ESA+ 
pancreatic CSCs sorted from HPAC-1 cells than in CD24-/CD44-/ESA- HPAC-1 cells. (F) Bar graph demonstrated that quantitative 
analysis of RT-PCR data.
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of PAUF, Sox2, and ALDH were lower in shPAUF 
CFPAC-1 than in control cells (Figure 3G).
Effects of PAUF on chemoresponse of pancreatic 
cancer cell lines
Past studies have suggested that pancreatic 
CSCs are more resistant to anti-cancer chemotherapy 
agents such as gemcitabine and 5-FU. To determine 
the role of PAUF in chemoresponse, we performed cell 
survival assays to validate cytotoxic effects of 5-FU 
or gemcitabine against PAUF-associated pancreatic 
cancer. Two transient siPAUF RNAs were used for this 
experiment.
Both siPAUF CFPAC-1 and siPAUF cells were 
more vulnerable to the two cytotoxic drugs than the 
control CFPAC-1 cells (p<0.05, Figure 4A–4B). 
Furthermore, mRNA expression of PAUF, multidrug 
resistant protein 5 (MRP5) and ribonucleotide reductase 
M2 (RRM2) was lower in siPAUF CFPAC-1 cells 
than in control cells (Figure 4C). These responses for 
knockdown effect of PAUF were in same manner in 
AsPC-1 cells (Figure 4D–4F).
DISCUSSION
Recent studies have demonstrated the presence of 
pancreatic CSCs, which are capable of self-renewal and 
production of differentiated progeny, in PDAC. Although 
the isolation and culturing of pancreatic CSCs remains 
difficult, the role of CSCs in development, maintenance, 
and metastasis of PDAC is increasingly recognized. In this 
study, we cultured the pancreatic cancer cells in serum-free 
media and obtained pancreatic cancer sphere cells, which 
had self-renewal capabilities. Relative to the adherent 
cells, PDAC spheres showed increased mRNA and 
protein expression of PAUF and the pluripotent stemness 
genes Oct4, Nanog, Sox2 and STAT3. Additionally, 
CD44+CD24+ESA+ pancreatic CSCs had increased mRNA 
expression of PAUF.
We recently identified PAUF, (also known as a 
paralog of ZG16B), a novel 27-kDa secretory protein 
Figure 3: PAUF knockdown effects on pancreatic cancer stem cells in pancreatic cancer cell lines. (A) PAUF knockdown 
CFPAC-1 cells were established by shRNA transfection, and shPAUF CFPAC-1 cells were confirmed using RT-PCR and western blot. 
Β-actin and GAPDH served as a loading control. (B) Migration assays showed that shPAUF CFPAC-1 cells had decreased migration ability 
compared with NC CFPAC-1 cells; 187.71 ± 41.33 cells/microscopic field in shPAUF vs. 278.67 ± 28.66 cells/microscopic field in NC 
(C) in vivo tumor cell xenograft assay showed shPAUF CFPAC-1 cells formed smaller size of tumor compared with NC CFPAC-1 cells; 
the average tumor size 114.5 ± 30.12 mm3 in shPAUF vs. 258.0 ± 103.0 mm3 in NC. (D) Sphere formation assays showed that shPAUF 
CFPAC-1 cells had a lower sphere-forming ability compared with NC CFPAC-1 cells. (E) Soft agar assays showed that shPAUF CFPAC-1 
cells had lower number of colonies compared with NC CFPAC-1 cells; 106.25 ±0.24 colonies in shPAUF vs. 195.25 ± 0.10 colonies in NC 
(F) RT-PCR demonstrated that the expression of pluripotent stemness genes and cancer stem cell-related genes were reduced in shPAUF 
CFPAC-1 cells compared with NC CFPAC-1 cells. (G) Western blot showed a lower protein expression of PAUF and cancer stem cell-
related proteins in shPAUF CFPAC-1 cells compared with NC CFPAC-1 cells.
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highly expressed in human PDAC [8]. As an autocrine 
factor, PAUF is involved in altered migration, invasion, 
proliferation, and metastasis [9, 11, 16]. PAUF also acts 
as a paracrine factor by causing stromal changes in the 
tumor microenvironment that promotes tumor evasion 
of the immune surveillance system [12]. PAUF also 
modulates permeability of the endothelial cells and 
vasculature to promote tumor angiogenesis [17]. Although 
only a few preclinical studies have investigated anti-PAUF 
monoclonal antibodies, PAUF-specific RNA aptamers 
(P12FR2), and adenoviral PAUF-targeting trans-splicing 
ribozymes (TSR) for PDAC, PAUF-targeted therapies 
may be an alternative approach for cancer treatment 
[10, 14, 15]. The above-mentioned studies suggest 
functional roles of PAUF in pancreatic cancer; however, 
little is known about the clinical relationship between 
PAUF and pancreatic CSCs. Therefore, we show the 
association between PAUF expression and characteristics 
of CSCs to determine the contribution of PAUF activity to 
chemoresponse in pancreatic CSCs,
Of clinical importance, recent research suggests 
CSCs are resistant to conventional chemotherapy and 
radiation [4]. Enhanced expression of ATP-binding 
cassette (ABC) family of transporters has been shown 
to be characteristic of side population cells with CSC 
features. These side population cells are more resistant 
to chemotherapeutic agents and may play a key role in 
tumor progression, recurrence, and metastasis [18, 19]. To 
identify the relationship between chemoresponse and the 
functional role of PAUF, we conducted cytotoxic studies 
with gemcitabine and 5-FU in siPAUF CFPAC-1/siPAUF 
AsPC-1 cells and negative controls. Our study showed that 
siPAUF CFPAC-1/siPAUF AsPC-1 cells were significantly 
more vulnerable to both cytotoxic drugs. Similar to our 
results, recent study reported that silencing of PAUF 
leads to increase the sensitivity to gemcitabine in BxPC-
3 cells and this mechanism may involve drug transporter 
such as MRP2, MRP3, and MDR1 genes [20]. However, 
because both chemosensitivity and chemoresistance 
can occur through intracellular enzymes regardless of 
drug transporters, we measured the mRNA expression 
of genes involved in drug metabolism (such as dCK, 
CDA, RRM1, and RRM2) in addition to transporters 
(including MRP3, MRP4, MRP5, and hENT1). In the 
present study, the both siPAUF CFPAC-1 and siPAUF 
AsPC-1 cells decreased mRNA expression of MRP5 and 
RRM2. MRP5 (also known as ABCC5) is a member of 
the multidrug resistance-associated protein subfamily 
of ABC transporters and confers resistance against 
chemotherapeutic drugs such as etoposide, 5-FU, and 
Figure 4: Effects of PAUF on chemoresponse of pancreatic cancer cell lines. (A-B) PAUF knockdown effects on the cytotoxicity 
of 72 hours inoculation with gemcitabine and 5FU in CFPAC-1 cells. MTT assay showed significantly increased antitumor effect of 
gemcitabine (A) and 5FU (B) in PAUF-silenced CFPAC-1 cells compared with negative control CFPAC-1. Data are shown as the mean 
± SD. (C) RT-PCR demonstrated mRNA expression of MRP5 and RRM2 was lower in the siPAUF CFPAC-1 cells than in the negative 
control CFPAC-1 cells. (D-E) PAUF knockdown effects on the cytotoxicity of 72 hours inoculation with gemcitabine and 5FU in AsPC-1 
cells. MTT assay showed significantly increased antitumor effect of gemcitabine (D) and 5FU (E) in PAUF-silenced AsPC-1 cells compared 
with negative control CFPAC-1. (F) RT-PCR demonstrated mRNA expression of MRP5 and RRM2 was lower in the siPAUF AsPC-1 cells 
than in the negative control AsPC-1 cells
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gemcitabine [21–23]. RRM2 is the catalytic subunit of 
ribonucleotide reductase, a dimeric enzyme that supplies 
deoxynucleotides essential for DNA replication and cell 
growth. The overexpression of RRM2 has been associated 
with gemcitabine resistance and increased cellular 
invasiveness in vitro [24], [25] and high expression of 
RRM2 in pancreatic tumors is associated with reduced 
overall survival after resection [26].
Taken together, our study indicated that PAUF 
signaling was required for the formation of pancreatic 
CSCs. In addition, the suppression of PAUF may 
contribute to increase drug sensitivity through mechanisms 
involving MRP5 and RRM2, thus making it a novel target 
for treatment of PDAC. However, our study had some 
limitations. First, we could not demonstrate a PAUF 
mediated signal transduction mechanism by which PAUF 
induces CSCs phenotypes. Second, we used pancreatic 
cancer cell lines rather than patient-derived pancreatic 
cancer cells and only investigated the effect of PAUF 
knockdown in PDAC cancer cell lines rather than in 
pancreatic CSCs derived from human tissues. Third, we 
did not perform the experimental study using in vivo 
models of human PDAC, which are required to prove 
a causal relationship between PAUF and target proteins 
such as MRP5 and RRM2. Thus, the possible connection 
between PAUF, drug transporters, and cell signaling 
pathways should be investigated in future studies.
In conclusion, we showed that PAUF is a novel 
protein overexpressed in human pancreatic CSCs that may 
contribute to chemosensitivity by decreasing MRP5 and 
RRM2. Thus, PAUF may constitute a therapeutic target to 
enhance the drug sensitivity of pancreatic CSCs.
MATERIALS AND METHODS
Cell culture
Four PDAC cell lines (AsPC-1, Capan-1, CFPAC-1, 
and HPAC) were obtained from ATCC(American 
Type Culture Collection). All cells were grown in the 
appropriate conditioned medium and maintained in an 
atmosphere of 5% CO2/95% air at 37˚C. We primarily 
used CFPAC-1, which expresses high endogenous levels 
of PAUF, for our experiments. In order to form cancer 
spheres, single cells were cultured for 7 days in Dulbecco’s 
Modified Eagle Medium: Nutrient Mixture 12 (DMEM/
F12,1:1; Gibco) containing 0.5% fetal bovine serum 
(FBS) (Hyclone), 0.5% bovine serum albumin fraction V 
Table 1: The sequences of PCR primer for the expression of known pancreatic CSCs related molecules
Name Sequence
ß-catenin (sense) GTATGAGTGGGAACAGGGATTT
ß-catenin (antisense) CCTGGTCCTCGTCATTTAGC
SOX2 (sense) CACAACTCGGAGATCAGCAA
SOX2 (antisense) GTTCATGTGCGCGTAACTGT
NANOG (sense) ACTGTCTCTCCTCTTCCTTCCT
NANOG (antisense) AGAGTAAAGGCTGGGGTAGGTA
OCT4 (sense) AAG TGG GTG GAG GAA GCT
OCT4 (antisense) CGA GGA GTA CAG TGC AGT
STAT3 (sense) GTCTGGCTGGACAATATCAT
STAT3 (antisense) TTGGGAATGTCAGGATAGAG
CD44 (sense) CACCATTTCAACCACACCAC
CD44 (antisense) GGTGTTGTCCTTCCTTGCAT
CD133 (sense) GCTCAGACTGGTAAATCCCC
CD133 (antisense) GACTCGTTGCTGGTGAATTG
c-MET (sense) CAA TGT GAG ATG TCT CCA GC
c-MET (antisense) CCT TGT AGA TTG CAG GCA GA
ALDH1A1 (sense) AGCAGGAGTGTTTACCAAAGA
ALDH1A1 (antisense) CCCAGTTCTCTTCCATTTCCAG
ABCG2 (sense) CAC TGA TCC TTC CAT CTT GT
ABCG2 (antisense) TAT GAG TGG CTT ATC CTG CT
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(Gibco), insulin-transferrin-selenium A (Gibco), 10 ng/ml 
human epidermal growth factor (hEGF; R&D systems, 
Wiesbaden-Nordenstadt, Germany), 10 ng/ml human 
fibroblast growth factor (hFGF; R&D), and 10 ng/ml 
human leukemia inhibitory factor (hLIF; R&D) at a 
density of 1×103 cells/ml in an ultralow attachment plate 
(Corning, Corning, NY, USA). Growth factors were added 
every 3 days. For preparation of secretory proteins, culture 
medium was changed to serum-free medium in the post 
sphere culture after 5 days and cultured for an additional 
2 days.
Semi-quantitative PCR (reverse transcription 
PCR)
The total RNA from cancer cells was extracted 
using a RNA easy extraction kit (Qiagen) according 
to the manufacturer’s instructions. To quantify the 
relative expression of the genes, we used β-actin 
primer as a control. The PCR primers used were PAUF 
sense, 5’-cacctgggcagggaagatgta-3’; PAUF antisense, 
5’-gctcagtggtcggctcctct-3’; β-actin sense, 5’-ggcatc 
ctcaccctgaagta –3’; and β-actin antisense, 5’-ggggtgttgaa 
ggtctcaaa-3’. The PCR primer sequences for the expression 
of genes related to pancreatic CSCs are described in 
 Table 1.
Establishment of stable PAUF knockdown cell 
line using shRNA
The shRNA-expressing plasmid targeting human 
PAUF and negative control plasmid were purchased from 
SABiosciences. The human PAUF shRNA sequence was 
5’-ACACCAGCAAGGACCGCTATT -3’ and the control 
shRNA sequence 5’-GGAATCTCATTCGATGCATAC -3’. 
For shRNA transfection, CFPAC-1 cells were plated 
into 6-well plates at a density of 5×104 cells/well the day 
before transfection. Transfection was performed using 
Lipofectamine2000 reagent according to manufacturer’s 
instructions, and stable knockdown clones were selected 
using neomycin.
Transient transfection of small interfering RNA 
(siRNA) targeted for PAUF
The two sets of 25-nucleotide stealth RNAi-targeting 
PAUF were synthesized customarily by Invitrogen. Stealth 
RNAi duplexes, which have a similar GC content to that 
of the duplex siRNA obtained from Invitrogen, were used 
as negative controls. Stealth RNAi-targeting PAUF were 
transfected into CFPAC-1 cells using Lipectamine™ 
RNAi Max transfection agent (Invitrogen) according to 
the manufacturer’s protocol. Cells were harvested 72 h 
post-transfection and subjected to total RNA extraction 
and a migration and invasion assay. Secreted protein was 
prepared from culture medium 48 h post-transfection.
MTT assay
After incubation at 37˚C overnight, cells were 
treated with various concentrations of gemcitabine 
or fluorouracil (5-FU) in complete growth media and 
incubated for 72 h at 37˚C. A 3-(4,5-dimenthelthiazol-
2-ly)-2,5-diphenyltetrasolium bromide-based assay 
(absorbance 570 nm) was used to measure the number of 
metabolically active cells.
Flow cytometry and cell sorting
Cultured cells were detached with accutase solution 
(Sigma-Aldrich, Inc., St. Louis, MO, USA) and washed 
in phosphate-buffered saline (PBS) containing 0.5% FBS. 
Single cells were stained for 20 min on ice in the dark, 
washed twice in PBS containing 0.5% FBS, and fixed 
in 2% paraformaldehyde. Flow cytometry analysis was 
performed using a FACSCalibur system (BS Biosciences, 
San Jose, CA), and cell sorting was performed using 
FACSAria II (BD Immunocytochemistry System, Franklin 
Lakes, NJ). Antibodies against CD24 (anti-CD24-PE, BD), 
CD44 (anti-CD44-APC, BD), and ESA (anti-ESA-FITC, 
BD) were used. FITC-mouse IgG2b, κ isotype control 
(BD), rat IgG1 κ isotype control FITC (eBioscience), PE-
mouse IgG2a, κ isotype control (BD), and APC-mouse 
IgG2b, κ isotype control (BD) were used as controls.
Protein extraction and western blot
Cells were prepared in lysis buffer containing 
50 mM HEPES (pH 7.2), 150 mM NaCl, 25 mM beta-
glycerophosphate, 25 mM NaF, 5 mM EGTA, 1 mM 
EDTA, 1% NP-40, 1 mM sodium orthovanadate, 0.1 mM 
phenylmethanesulfonylfluoride (PMSF), and a 
protease inhibitor cocktail (Roche Diagnostics). For 
secretory protein preparation, culture medium was 
centrifuged and the cellular components and debris 
were discarded. Culture medium was concentrated by 
the addition of ice-cold acetone, and the precipitated 
protein was resuspended with lysis buffer. Proteins 
were separated on SDS-PAGE and transferred to 
0.45-μm Immobilon P-transfer membrane (Millipore). 
Membrane was blocked in 5% (w/v) non-fat milk and 
probed with the following primary antibodies: anti-
human PAUF antibody (2009 Cancer Science), Sox2 
(Cell Signaling Technology), Oct4 (Cell Signaling 
Technology), Nanog (Cell Signaling Technology), 
aldehyde dehydrogenase (ALDH) (BD), Cdk6 (Santa 
Cruz), cyclin D3 (Santa Cruz), Snail (Cell Signaling 
Technology), slug (Cell Signaling Technology), twist 
(Cell Signaling Technology) and glyceraldehyde 
phosphate dehydrogenase (GAPDH) (Santa Cruz). 
Immunoreactive material was then visualized using 
SuperSignal West Pico Chemiluminescence Substrate 
[27] according to the manufacturer’s instructions.
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Soft agar assay
A suspension of 500 single cells containing 0.3% 
agar medium was overlaid on 0.6% agar medium in 24-
well plates. Each well was covered with complete medium, 
and the plates were incubated for 4 weeks. Colonies were 
stained with crystal violet and counted. Experiments were 
done in triplicate.
Cell proliferation, migration and invasion assay
For cell proliferation, 2 x 103 cells were seeded per 
sell into 24 well plates. Every 24 h, the number of cells 
was counted. The experimental was done in triplicate to 
determine the number of cells at each time point. The 
migration assays were performed in 6-well Transwell 
plates (Costar, Cambridge, MA). Cells (1 × 105) 
were seeded in triplicate in the upper compartment. The 
media incubated the NIH/3T3 with DMEM for 24 hours 
was added to the lower wells. Following 24-hour 
incubation at 37C in a 5% CO2 humidified incubator 
the cells in the upper chamber and on the surface of 
the filter were completely removed by wiping with a 
moist cotton swab. Cells that had migrated through the 
filter and adhered to the outer surface were fixed with 
methanol and stained with Toluidine Blue. Invading 
cells were examined, counted and photographed by 
microscopy at 100× magnification. The invasive 
abilities were tested by Matrigel invasion assay. Assays 
were performed in 6-well Transwell plates (Costar, 
Cambridge, MA) with an 8 μm pore size were coated 
with Matrigel (Becton Dickinson). Cells (1 × 105) were 
then seeded in triplicate in the upper compartment 
chamber coated with Matrigel. The media incubated 
the NIH/3T3 with DMEM for 24 hours was added to 
the lower wells. Following 48-hour incubation at 37C 
in a 5% CO2 humidified incubator the cells in the upper 
chamber and on the surface of the filter were completely 
removed by wiping with a moist cotton swab. Cells 
that had invaded the Matrigel, migrated through the 
filter and adhered to the outer surface were fixed with 
methanol and stained with Toluidine Blue. Invading 
cells were examined, counted and photographed by 
microscopy at 100× magnification.
In vivo tumorigenic assay
Cells were resuspended at a cell density of 
3x 106 cells in 150 μl of serum-free culture medium 
and injected subcutaneously into the BALB/c nude 
female mice (6 weeks of age). Tumor formation was 
monitored twice a week measuring the width and 
length. Tumor volumes were calculated by the formula 
V (mm3) = A x B2, where A is the largest dimension and 
B is the perpendicular diameter. Tumor xenografts were 
recovered from mice, fixed in 4% paraformaldehyde, 
and embedded in paraffin.
Statistical analysis
Mann-Whitney U test and independent t-test were 
used to compare cell survival between siPAUF and control 
groups. Statistical calculations were performed using 
SPSS (version 12.0 for Windows; SPSS, Inc., Chicago, 
IL, USA). Values of p < 0.05 were considered statistically 
significant. For quantitative analysis western blot and 
RT-PCR data, we used ImageJ softwere (U.S. National 
Institutes of Health, Bethesda, MD, https://imagej.nih.
gov/ij).
Acronyms list
Pancreatic ductal adenocarcinoma: PDAC
Cancer stem cells: CSCs
Pancreatic adenocarcinoma up-regulated factor: 
PAUF
Octamer-binding transcription factor 4: Oct4
Signal transducer and activator of transcription 3: 
Stat3
Sex determining region Y-box 2: Sox2
Epithelial-specific antigen: ESA
Aldehyde dehydrogenase: ALDH
Phosphatase and tensin homolog: PTEN
Lymphoid enhancer-binding factor 1: Lef1
Dishevelled segment polarity protein 2: Dvl2
Multidrug resistant protein: MRP
Ribonucleotide reductase M: RRM
American Type Culture Collection: ATCC
Human epidermal growth factor: hEGF;
Human fibroblast growth factor: hFGF
Human leukemia inhibitory factor: hLIF;
Fluorescence-activated cell sorting: FACS
Cyclin-dependent kinase 6: CDK6
Deoxycytidine kinase: dCK
Equilibrative nucleoside transporter 1: ENT1
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